Cost Of Illness Pengobatan Pasien Cronic Kidney Disease dengan Hemodialisa di Instalasi Rawat Jalan RS Soerojo Magelang

Cost of Illness Treatment for Chronic Kidney Disease Patients with Hemodialysis in the Outpatient Installation of Soerojo Hospital, Magelang

Authors

  • Nurfina Dian Kartikawati Program Studi D3 Farmasi, Universitas Muhammadiyah Magelang, Magelang, Indonesia Author
  • Widarika Santi Hapsari Program Studi D3 Farmasi, Universitas Muhammadiyah Magelang, Magelang, Indonesia Author
  • Septiayu Dwi Hartienah Program Studi Sarjana Farmasi, Universitas Mulawarman, Samarinda, Indonesia Author

DOI:

https://doi.org/10.30872/jsk.v7i2.1046

Keywords:

Analisis Biaya, Biaya Medis, Chronic Kidney Disease

Abstract

Chronic kidney disease (CKD) ditandai dengan adanya kerusakan ginjal atau laju filtrasi glomerulus (eGFR) yang diperkirakan kurang dari 60 mL/menit/1,73 m² yang berlangsung selama 3 bulan atau lebih. Data Kementerian Kesehatan pada tahun 2015 menunjukkan setidaknya hingga tahun 2015 terdapat penambahan 2000 kasus baru per tahun untuk pasien ginjal kronis yang sudah pada stadium akhir dan lebih dari 10% pasien ginjal kronis menjalani hemodialisis. Penelitian ini bertujuan untuk menganalisis biaya pengobatan pasien CKD di RS Soerojo dan melihat komponen-komponen biayanya. Data diperoleh secara retrospektif melalui rekam medis periode Januari-Desember 2024 di RS Soerojo. Kriteria inklusi meliputi pasien dengan usia >18 tahu dan memiliki data pasien ataupun data keuangan yang lengkap. Analisis statistik yang digunakan adalah statistik deskriptif, distribusi varian dan uji Mann-Whitney. Hasil penelitian menunjukkan 144 pasien memenuhi kriteria inklusi dengan karakteristik usia yang paling dominan adalah 50-59 tahun (58,83%); laki-laki sebesar 63,89%, stage 5 sebesar 91,57%; tanpa komorbid sebanyak 70,14%; penggunaan 1-5 item obat 84,72%. Secara keseluruhan rata-rata biaya paling tinggi terdapat pada pasien stage 5 sebesar 971.220 setiap kali kedatangan. Terdapat perbedaan secara signifikan secara statistik pada rata-rata biaya medis langsung (p<0,05) pada stage CKD dan jumlah penyakit penyerta.

References

[1] M. Nisar et al., “The direct cost of chronic kidney disease (CKD) reported in Asian countries; a systematic literature review,” Cost Effectiveness and Resource Allocation, vol. 22, no. 1, p. 65, Sep. 2024, doi: 10.1186/s12962-024-00566-9.

[2] C. W. G. KDIGO, “KDIGO 2024 Clinical Practice Guideline for the Evaluastion and Management of Chronic Kideney Disease,” Kidney International, vol. 105, no. 4, p. A1, Apr. 2024, doi: 10.1016/S0085-2538(24)00110-8.

[3] N. M. Hustrini, “Chronic Kidney Disease Care in Indonesia: Challenges and Opportunities,” Acta Medica Indonesiana, vol. 55, no. 1, pp. 1–1, Mar. 2023.

[4] S. Sari, Z. Suhada, and T. Triagustini, “Cost of illness pasien gagal ginjal kronis di Rumah Sakit Umum Daerah Arifin Achmad Provinsi Riau,” Jurnal Ilmiah Farmasi, vol. 19, no. 2, pp. 113–125, Dec. 2023, doi: 10.20885/jif.vol19.iss2.art10.

[5] E. Sunariyanti, T. M. Andayani, D. Endarti, and D. A. Puspandari, “Cost Analysis of Chronic Kidney Disease Patients in Indonesia,” Clinicoecon Outcomes Res, vol. 15, pp. 621–629, 2023, doi: 10.2147/CEOR.S388547.

[6] Fauziah, D. Wahyono, and L. E. Budiarti, “Cost Of Illness Dari Chronic Kidney Disease Dengan Tindakan Hemodialisis,” Jurnal Manajemen Dan Pelayanan Farmasi (Journal of Management and Pharmacy Practice), vol. 5, pp. 149–158, 2015.

[7] J. Mende, N. D. Kartikawati, A. Titami, and H. Mahmuda, “Principles Of Dose Adjustment In Patients With Chronic Kidney Failure,” Jurnal Farmasi Sains dan Praktis, pp. 115–126, 2025.

[8] I. Hadning, H. Hendrawan, and W. K. Rahayu, “Cost of illness of chronic kidney disease patients with hemodialysis in Yogyakarta Indonesia,” in AIP Conference Proceedings, AIP Publishing, 2024.

[9] A. R. Villanueva et al., “Cost-of-illness analysis of chronic kidney disease (CKD) management in the Philippines,” Journal of Medical Economics, vol. 28, no. 1, pp. 494–507, Dec. 2025, doi: 10.1080/13696998.2025.2481766.

[10] R. Andhika et al., “One-year Survival of End-Stage Kidney Disease Patients Undergoing Hemodialysis in Indonesia,” Int J Nephrol Renovasc Dis, vol. 18, pp. 87–101, Mar. 2025, doi: 10.2147/IJNRD.S508012.

[11] R. Nindela, S. N. Prastowo, E. F. Zulissetiana, S. Marisdina, and S. S. F. Putri, “Impact of Age Initiation and Duration of Hemodialysis on Impaired Cognitive Function Experienced by Chronic Kidney Disease (CKD) Patients,” Jurnal Profesi Medika : Jurnal Kedokteran dan Kesehatan, vol. 18, no. 1, pp. 36–43, Jun. 2024, doi: 10.33533/jpm.v18i1.7830.

[12] M. Hecking et al., “Sex-Specific Differences in Mortality and Incident Dialysis in the Chronic Kidney Disease Outcomes and Practice Patterns Study,” Kidney Int Rep, vol. 7, no. 3, pp. 410–423, Dec. 2021, doi: 10.1016/j.ekir.2021.11.018.

[13] N. D. Kartikawati, T. M. Andayani, and D. Endarti, “Gambaran dan Luaran Klinik Terapi Anemia Pada Pasien Chronic Kidney Disease Dengan Hemodialisis Di RS PKU Muhammadiyah Yogyakarta,” Majalah Farmaseutik, vol. 19, no. 1, pp. 148–154, 2023.

[14] S. R. Vaidya and N. R. Aeddula, Chronic Renal Failure. StatPearls Publishing, 2020. Accessed: Mar. 18, 2021. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK535404/

[15] D. T. Zainal, D. G. Tamtomo, and B. Murti, “Correlation between the Characteristics of Chronic Kidney Disease Patients Undergoing Hemodialysis and Erythropoietin Stimulating Agent Therapy and Hemoglobin Levels,” Indonesian Journal of Medicine, vol. 9, no. 2, pp. 145-`155, Apr. 2024, doi: 10.26911/theijmed.2024.9.2.715.

[16] H. N. Murdeshwar and F. Anjum, “Hemodialysis,” in StatPearls, Treasure Island (FL): StatPearls Publishing, 2025. Accessed: Sep. 02, 2025. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK563296/

[17] S. Tanaka, T. Nakano, H. Hiyamuta, K. Tsuruya, and T. Kitazono, “Association between Multimorbidity and Kidney Function among Patients with Non-Dialysis-Dependent CKD: The Fukuoka Kidney Disease Registry Study,” J Atheroscler Thromb, vol. 29, no. 8, pp. 1249–1264, Aug. 2022, doi: 10.5551/jat.62900.

[18] C. MacRae, S. W. Mercer, B. Guthrie, and D. Henderson, “Comorbidity in chronic kidney disease: a large cross-sectional study of prevalence in Scottish primary care,” Br J Gen Pract, vol. 71, no. 704, pp. e243–e249, Feb. 2021, doi: 10.3399/bjgp20X714125.

[19] C. Kyriakopoulos and V. Gupta, “Renal Failure Drug Dose Adjustments,” in StatPearls, Treasure Island (FL): StatPearls Publishing, 2023. Accessed: Oct. 28, 2023. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK560512/

[20] X. Liu, P. Chen, Y. Liu, X. Jia, and D. Xu, “Medication burden in patients with dialysis-dependent CKD: a systematic review,” Ren Fail, vol. 46, no. 1, p. 2353341, doi: 10.1080/0886022X.2024.2353341.

[21] H. Jyrkilä et al., “Comorbidity and Medication Trends in Chronic Kidney Disease and Incident Atrial Fibrillation: A Nationwide Cohort Study,” Nephron, vol. 148, no. 11–12, pp. 755–767, Jun. 2024, doi: 10.1159/000539603.

Downloads

Published

2026-05-29

Deprecated: json_decode(): Passing null to parameter #1 ($json) of type string is deprecated in /home/jskff/public_html/plugins/generic/citations/CitationsPlugin.php on line 68

How to Cite

[1]
N. D. Kartikawati, W. S. Hapsari, and Septiayu Dwi Hartienah, “Cost Of Illness Pengobatan Pasien Cronic Kidney Disease dengan Hemodialisa di Instalasi Rawat Jalan RS Soerojo Magelang: Cost of Illness Treatment for Chronic Kidney Disease Patients with Hemodialysis in the Outpatient Installation of Soerojo Hospital, Magelang”, J. Sains. Kes, vol. 7, no. 2, pp. 143–149, May 2026, doi: 10.30872/jsk.v7i2.1046.

Similar Articles

101-110 of 231

You may also start an advanced similarity search for this article.